INO Inovio Pharmaceuticals
- 12.0100
- +0.4200+3.62%
- 12.0000
- -0.0100-0.08%
Inovio Pharmaceuticals News
Press Release: INOVIO Reports Inducement Grants Under Inducement Plan
INOVIO Reports Inducement Grants Under Inducement Plan PR Newswire PLYMOUTH MEETING, Pa., May 1, 2024 PLYMOUTH MEETING, Pa., May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology compa
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
INOVIO to Participate in Upcoming Investor Conferences in May
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...
Inovio Pharmaceuticals Form 13G Shows Deep Track Capital, LP Reported A 9.99% Stake In The Co As Of April, 16, 2024
Inovio Pharmaceuticals Form 13G Shows Deep Track Capital, LP Reported A 9.99% Stake In The Co As Of April, 16, 2024
Inovio Pharmaceuticals Stock Is Diving Today: What's Happening?
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares are trading lower Tuesday after the company announced the pricing of a public offering.
INOVIO Shares Are Trading Lower After the Company Announced the Pricing of Its $36 Million Underwritten Offering.
INOVIO Shares Are Trading Lower After the Company Announced the Pricing of Its $36 Million Underwritten Offering.
Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants
Inovio Pharmaceuticals (INO) shares slid 24% in premarket activity Tuesday after the company said late Monday that it priced its underwritten offering of common stock and pre-funded warrants, for gros
Top Premarket Decliners
Ryvyl (RVYL) shares fell 39% after the company said it has launched a public offering of shares. Skillsoft Corp. (SKIL) shares dropped 20% after the company posted lower fiscal Q4 revenue. Inovio Phar
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
Inovio Falls After Pricing Stock Offering
Reported Earlier, INOVIO Prices $36M Underwritten Offering Of 2,536,258 Common Stock At $7.693/Share
INOVIO Pharmaceuticals announced the pricing of an underwritten offering of 2,536,258 shares of its common stock at an offering price of $7.693 per share and pre-funded warrants to purchase 2,135,477
Inovio Shares Fall 23% After Underwritten Offering Prices
By Stephen Nakrosis Shares of biotechnology company Inovio were trading lower in the after-hours market following news it priced an underwritten offering of stock and warrants. After the bell Monday
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
PLYMOUTH MEETING, Pa., April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pro
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
Inovio Pharmaceuticals: A Strong Buy on Promising IL-12 Therapy Developments and Market Interest
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re
Peering Into Inovio Pharmaceuticals's Recent Short Interest
Inovio Pharmaceuticals's (NYSE:INO) short percent of float has risen 22.31% since its last report.
Inovio Pharma Is Maintained at Outperform by Oppenheimer
Inovio Pharma Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Maintains $40 Price Target
Oppenheimer analyst Hartaj Singh maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Outperform and maintains $40 price target.
RBC Capital Reiterates Sector Perform on Inovio Pharmaceuticals, Maintains $11 Price Target
RBC Capital analyst Gregory Renza reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Sector Perform and maintains $11 price target.
Analysis
Price Target
No Data
